Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
暂无分享,去创建一个
R. Salazar | E. Van Cutsem | G. Bodoky | P. Rougier | D. Cunningham | P. Mainwaring | C. Karapetis | B. Mookerjee | H. Schmoll | A. Sobrero | I. Bondarenko | I. Kocáková | P. Barker | S. Koski | J. Robertson
[1] R. Labianca,et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Ying Cheng,et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Daniel J. Sargent,et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) , 2012 .
[4] T. Choueiri,et al. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. , 2011, Critical reviews in oncology/hematology.
[5] H. Staines,et al. A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer , 2011 .
[6] J. Tabernero,et al. Intravenous (IF) Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): Results of a multinational phase III trial (EFC10262-VELOUR) , 2011 .
[7] R. Labianca,et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] D. Kerr,et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Hoff,et al. Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Zena Wilson,et al. Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family , 2011, Molecular Cancer Therapeutics.
[11] A. Shields,et al. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study , 2011, Investigational New Drugs.
[12] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Giaccone,et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. , 2010, European journal of cancer.
[15] L. Seymour,et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Pond,et al. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Percy Ivy,et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Murakami,et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors , 2009, Cancer Chemotherapy and Pharmacology.
[19] L. Seymour,et al. Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-fluorouracil in Patients with Advanced Colorectal Cancer Cancer Therapy: Clinical , 2022 .
[20] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[21] J. Hainsworth,et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Carroll,et al. Analysis of duration of response in oncology trials. , 2008, Contemporary clinical trials.
[23] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Seymour,et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Drevs,et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Drevs,et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors , 2005 .
[27] F. Kabbinavar,et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Barry,et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.
[29] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[30] W. Scheithauer,et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] J Whitehead,et al. The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. , 1989, Statistics in medicine.